NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial.

ABSTRACT:

Background

Metastatic prostate cancer is commonly treated with androgen deprivation therapy (ADT) and chemotherapy, which often leads to treatment resistance and disease progression with limited effective interventions. Recent advances in robotic surgery and precision radiotherapy have prompted research into comprehensive treatments for low-burden metastatic prostate cancer, particularly oligometastatic prostate cancer (OMPC). Our phase I/II clinical study confirmed the safety and efficacy of neoadjuvant radiotherapy combined with endocrine therapy before radical prostatectomy, warranting further investigation.

Methods

This study protocol outlines a prospective, open-label, multicenter, randomized controlled trial to evaluate preoperative neoadjuvant radiohormonal therapy ve

SUBMITTER: Fan Z 

PROVIDER: S-EPMC12020225 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature